Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.
The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...
Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment
Zabalafin Hydrogel is a novel, first-in-class complex single-source botanical drug with multiple bioactive compounds that provide multiple mechanisms of action, including anti-pruritic (anti-itch ...
TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer –– Investigational New Drug (IND) application for TNG456, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback